Literature DB >> 16720557

Bilateral osteonecrosis of the head of the femur during treatment with retinoic acid in a young patient with acute promyelocytic leukemia.

Miho Sakakura1, Kazuhiro Nishii, Eiji Usui, Fumihiko Monma, Tetsuya Tsukada, Hiroshi Shiku.   

Abstract

All-trans retinoic acid (ATRA) is the drug of choice for the treatment of acute promyelocytic leukemia (APL). In general, ATRA is well tolerated, but it does have side effects, the most severe of which is ATRA syndrome. We report the case of a young patient with APL treated with ATRA for induction and maintenance therapy who then developed avascular necrosis of both femoral heads. We also review cases of APL patients with osteonecrosis of the femoral head after ATRA therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720557     DOI: 10.1532/IJH97.E0515

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  12 in total

1.  All-trans retinoic acid and side-effects.

Authors:  C H Toh; D A Winfield
Journal:  Lancet       Date:  1992-05-16       Impact factor: 79.321

Review 2.  Nontraumatic avascular necrosis of the femoral head. Past, present, and future.

Authors:  J Arlet
Journal:  Clin Orthop Relat Res       Date:  1992-04       Impact factor: 4.176

3.  All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia.

Authors:  V Runde; C Aul; A Heyll; W Schneider
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

4.  Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits.

Authors:  G J Wang; D E Sweet; S I Reger; R C Thompson
Journal:  J Bone Joint Surg Am       Date:  1977-09       Impact factor: 5.284

5.  Avascular necrosis of head of femur in a patient with acute promyelocytic leukemia.

Authors:  D Abhyankar; R Nair; H Menon; B Kapoor; S Advani
Journal:  Leuk Lymphoma       Date:  2000-05

6.  Bilateral osteonecrosis of the head of the femur complicating acute promyelocytic leukemia: a sequel to treatment of retinoic acid syndrome with dexamethasone.

Authors:  S al-Bahar; R Pandita; A V Hoffbrand
Journal:  Acta Haematol       Date:  1996       Impact factor: 2.195

7.  Bone marrow necrosis in two patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid.

Authors:  S A Limentani; J O Pretell; D Potter; J S DuBois; P R Daoust; P S Spieler; K B Miller
Journal:  Am J Hematol       Date:  1994-09       Impact factor: 10.047

8.  Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia.

Authors:  Maurizio Aricò; Marie France Pinta Boccalatte; Daniela Silvestri; Elena Barisone; Chiara Messina; Robert Chiesa; Nicola Santoro; Paolo Tamaro; Alma Lippi; Domenico Gallisai; Giuseppe Basso; Giulio De Rossi
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

9.  Sickle cell disease as a cause of osteonecrosis of the femoral head.

Authors:  P F Milner; A P Kraus; J I Sebes; L A Sleeper; K A Dukes; S H Embury; R Bellevue; M Koshy; J W Moohr; J Smith
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

10.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

Authors:  R P Warrell; S R Frankel; W H Miller; D A Scheinberg; L M Itri; W N Hittelman; R Vyas; M Andreeff; A Tafuri; A Jakubowski
Journal:  N Engl J Med       Date:  1991-05-16       Impact factor: 91.245

View more
  2 in total

1.  Avascular Necrosis of Bone following Chemotherapy in Cancer Patients with Coagulopathy: Report of Two Cases.

Authors:  Hui-Ching Hsu; Tzu-Yao Liao; Dave Wei-Chih Chen; Yu-Hsiang Juan; Chuang-Chi Liaw
Journal:  Case Rep Oncol       Date:  2018-03-27

2.  Avascular necrosis of the hip and diffuse idiopathic skeletal hyperostosis during long-term isotretinoin treatment of epidermolytic ichthyosis due to a novel deletion mutation in KRT10.

Authors:  R C Lamb; J Lang; A Terron-Kwiatowski; D Baty; W H I McLean; M Zamiri
Journal:  Br J Dermatol       Date:  2014-08-05       Impact factor: 9.302

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.